MX2022007350A - Derivados de pirazolilo utiles como agentes anticancerigenos. - Google Patents
Derivados de pirazolilo utiles como agentes anticancerigenos.Info
- Publication number
- MX2022007350A MX2022007350A MX2022007350A MX2022007350A MX2022007350A MX 2022007350 A MX2022007350 A MX 2022007350A MX 2022007350 A MX2022007350 A MX 2022007350A MX 2022007350 A MX2022007350 A MX 2022007350A MX 2022007350 A MX2022007350 A MX 2022007350A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer agents
- derivatives useful
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud proporciona un compuesto de fórmula (I) o un estereoisómero del mismo, o un atropisómero del mismo, o una sal farmacéuticamente aceptable del mismo, o una sal farmacéuticamente aceptable de un estereoisómero del mismo, o una sal farmacéuticamente aceptable de un atropisómero del mismo; (ver Fórmula) (I) método para fabricar dicho compuesto, y sus usos terapéuticos. La presente solicitud proporciona además una combinación de agentes farmacológicamente activos y una composición farmacéutica que comprende dicho compuesto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951400P | 2019-12-20 | 2019-12-20 | |
| PCT/CN2020/125425 WO2021120890A1 (en) | 2019-12-20 | 2020-10-30 | Pyrazolyl derivatives useful as anti-cancer agents |
| PCT/IB2020/062144 WO2021124222A1 (en) | 2019-12-20 | 2020-12-17 | Pyrazolyl derivatives useful as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007350A true MX2022007350A (es) | 2022-07-19 |
Family
ID=76477081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007350A MX2022007350A (es) | 2019-12-20 | 2020-12-17 | Derivados de pirazolilo utiles como agentes anticancerigenos. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11702409B2 (es) |
| EP (2) | EP4344702A3 (es) |
| JP (3) | JP7726883B2 (es) |
| KR (1) | KR20220114064A (es) |
| CN (1) | CN114929342A (es) |
| AR (1) | AR120855A1 (es) |
| AU (1) | AU2020410531B2 (es) |
| CA (1) | CA3165148A1 (es) |
| CL (1) | CL2022001625A1 (es) |
| CO (1) | CO2022008344A2 (es) |
| CR (1) | CR20220281A (es) |
| DK (1) | DK4076662T3 (es) |
| DO (1) | DOP2022000124A (es) |
| EC (1) | ECSP22047876A (es) |
| ES (1) | ES2987196T3 (es) |
| FI (1) | FI4076662T3 (es) |
| HR (1) | HRP20240513T1 (es) |
| HU (1) | HUE066235T2 (es) |
| IL (1) | IL293893A (es) |
| JO (1) | JOP20220155A1 (es) |
| LT (1) | LT4076662T (es) |
| MA (1) | MA58004B1 (es) |
| MX (1) | MX2022007350A (es) |
| PE (1) | PE20221910A1 (es) |
| PH (1) | PH12022551454A1 (es) |
| PL (1) | PL4076662T3 (es) |
| PT (1) | PT4076662T (es) |
| RS (1) | RS65419B1 (es) |
| SI (1) | SI4076662T1 (es) |
| TW (1) | TW202136241A (es) |
| UY (1) | UY38990A (es) |
| WO (2) | WO2021120890A1 (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| PE20221253A1 (es) | 2019-10-28 | 2022-08-16 | Merck Sharp & Dohme | Inhibidores de pequenas moleculas de mutante g12c de kras |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| JOP20220160A1 (ar) | 2019-12-20 | 2023-01-30 | Nuevolution As | مركبات فعّالة نحو مستقبلات نووية |
| US20230212164A1 (en) | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| AR123313A1 (es) * | 2020-08-24 | 2022-11-16 | Adama Makhteshim Ltd | Proceso para la preparación de pirazoles sustituidos |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| EP4237412A4 (en) * | 2020-10-30 | 2024-04-10 | Novartis AG | NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| MX2023007399A (es) * | 2020-12-22 | 2023-07-06 | Novartis Ag | Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer. |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| US20240317721A1 (en) * | 2021-06-23 | 2024-09-26 | Novartis Ag | Pyrazolyl derivatives as inhibitors of the kras mutant protein |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| EP4441050A1 (en) * | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP2024543967A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガン処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| US20250282782A1 (en) | 2021-12-17 | 2025-09-11 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| MX2024007780A (es) | 2021-12-22 | 2024-09-11 | Univ California | Inhibidores de unión covalente de mutantes g12s, g12d y/o g12e de k-ras gtpasa. |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| TW202332434A (zh) * | 2022-01-31 | 2023-08-16 | 瑞士商諾華公司 | 可用作抗癌劑的吡唑基衍生物之合成方法 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| AU2023380159A1 (en) | 2022-11-18 | 2025-05-15 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| IL320913A (en) | 2022-11-21 | 2025-07-01 | Treeline Biosciences Inc | Spirocyclic dihydropyranopyrimidine KRAS inhibitors |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| WO2024215863A2 (en) * | 2023-04-13 | 2024-10-17 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024220470A1 (en) | 2023-04-17 | 2024-10-24 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof in the treatment of proliferative disorders |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025203012A1 (en) | 2024-03-27 | 2025-10-02 | Novartis Ag | Kras g12c inhibitor for use for the treatment of non-small cell lung cancer |
| WO2025202971A1 (en) | 2024-03-27 | 2025-10-02 | Novartis Ag | Kras g12c inhibitor for use for the treatment of non-small cell lung cancer |
| US12358315B1 (en) | 2024-03-29 | 2025-07-15 | Max Co., Ltd. | Long medium |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| EP1786803A1 (en) | 2004-08-31 | 2007-05-23 | Biogen Idec MA, Inc. | Pyrimidinylpyrazoles as tgf-beta inhibitors |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
| JP2009530261A (ja) * | 2006-03-16 | 2009-08-27 | ファイザー・プロダクツ・インク | ピラゾール化合物 |
| US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| AU2008276521B2 (en) * | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| EA201000113A1 (ru) * | 2007-08-01 | 2010-08-30 | Пфайзер Инк. | Пиразольные соединения |
| BRPI0916356B1 (pt) * | 2008-07-24 | 2022-08-23 | Nerviano Medical Sciences S.R.L | 3,4-diaril pirazois como inibidores da proteína quinase |
| WO2010108268A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2601185B1 (en) * | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| CN103732588B (zh) * | 2011-07-27 | 2016-10-12 | 南京奥昭生物科技有限公司 | 螺环分子作为蛋白激酶抑制剂 |
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| MX364438B (es) | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| UA119971C2 (uk) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Інгібітори g12c kras |
| JP6527163B2 (ja) | 2014-01-09 | 2019-06-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリミジンピラゾリル誘導体及びｉｒａｋ阻害剤としてのその使用 |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3409673B1 (en) | 2016-01-26 | 2021-06-16 | Hangzhou Bangshun Pharmaceutical Co., Ltd. | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
| JP2020500177A (ja) | 2016-11-14 | 2020-01-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ３，４−ビピリジルピラゾール誘導体、およびその製造方法およびその医療応用 |
| CN108069955B (zh) * | 2016-11-14 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用 |
| SI3558955T1 (sl) | 2016-12-22 | 2021-12-31 | Amgen Inc., | Derivati benzizotiazola, izotiazola(3,4-b)piridina, kinazolina, ftalazina, pirido(2,3-d)piridazina in pirido(2,3-D)pirimidina, kot zaviralci KRAS G12C za zdravljenje pljučnega raka, raka trebušne slinavke ali kolorektalnega raka |
| WO2018140598A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2019136147A1 (en) * | 2018-01-03 | 2019-07-11 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor signaling inhibitors |
| KR102861944B1 (ko) * | 2018-02-23 | 2025-09-26 | 사뮤메드, 엘엘씨 | 5-헤테로아릴 치환된 인다졸-3-카복사미드 및 그의 제조 및 용도 |
| JP7266043B2 (ja) * | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| MA52765A (fr) * | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| AR119271A1 (es) * | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
-
2020
- 2020-10-30 WO PCT/CN2020/125425 patent/WO2021120890A1/en not_active Ceased
- 2020-12-17 UY UY0001038990A patent/UY38990A/es not_active Application Discontinuation
- 2020-12-17 HR HRP20240513TT patent/HRP20240513T1/hr unknown
- 2020-12-17 ES ES20829365T patent/ES2987196T3/es active Active
- 2020-12-17 PE PE2022001123A patent/PE20221910A1/es unknown
- 2020-12-17 JP JP2022536692A patent/JP7726883B2/ja active Active
- 2020-12-17 FI FIEP20829365.4T patent/FI4076662T3/fi active
- 2020-12-17 SI SI202030406T patent/SI4076662T1/sl unknown
- 2020-12-17 PH PH1/2022/551454A patent/PH12022551454A1/en unknown
- 2020-12-17 PL PL20829365.4T patent/PL4076662T3/pl unknown
- 2020-12-17 PT PT208293654T patent/PT4076662T/pt unknown
- 2020-12-17 US US17/125,335 patent/US11702409B2/en active Active
- 2020-12-17 RS RS20240437A patent/RS65419B1/sr unknown
- 2020-12-17 EP EP24151713.5A patent/EP4344702A3/en active Pending
- 2020-12-17 HU HUE20829365A patent/HUE066235T2/hu unknown
- 2020-12-17 JO JOP/2022/0155A patent/JOP20220155A1/ar unknown
- 2020-12-17 LT LTEPPCT/IB2020/062144T patent/LT4076662T/lt unknown
- 2020-12-17 IL IL293893A patent/IL293893A/en unknown
- 2020-12-17 MX MX2022007350A patent/MX2022007350A/es unknown
- 2020-12-17 CR CR20220281A patent/CR20220281A/es unknown
- 2020-12-17 MA MA58004A patent/MA58004B1/fr unknown
- 2020-12-17 CN CN202080089867.2A patent/CN114929342A/zh active Pending
- 2020-12-17 DK DK20829365.4T patent/DK4076662T3/da active
- 2020-12-17 KR KR1020227024285A patent/KR20220114064A/ko not_active Ceased
- 2020-12-17 AU AU2020410531A patent/AU2020410531B2/en not_active Ceased
- 2020-12-17 CA CA3165148A patent/CA3165148A1/en active Pending
- 2020-12-17 EP EP20829365.4A patent/EP4076662B1/en active Active
- 2020-12-17 WO PCT/IB2020/062144 patent/WO2021124222A1/en not_active Ceased
- 2020-12-18 TW TW109145169A patent/TW202136241A/zh unknown
- 2020-12-21 AR ARP200103593A patent/AR120855A1/es not_active Application Discontinuation
-
2022
- 2022-06-15 CL CL2022001625A patent/CL2022001625A1/es unknown
- 2022-06-15 CO CONC2022/0008344A patent/CO2022008344A2/es unknown
- 2022-06-15 EC ECSENADI202247876A patent/ECSP22047876A/es unknown
- 2022-06-15 DO DO2022000124A patent/DOP2022000124A/es unknown
-
2024
- 2024-01-22 JP JP2024007468A patent/JP2024056707A/ja not_active Withdrawn
-
2025
- 2025-06-06 JP JP2025095128A patent/JP2025143289A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007350A (es) | Derivados de pirazolilo utiles como agentes anticancerigenos. | |
| DOP2022000183A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| CO6781541A2 (es) | Derivados glucósidos y usos de los mismos | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| UY36124A (es) | Derivados de carboxamida | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| UY36123A (es) | Derivados de carboxamida | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| CL2022002490A1 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| CO2022004768A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR131249A1 (es) | Derivados de heteroarilo bicíclicos útiles como agentes anticancerígenos | |
| MX2024001613A (es) | Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo. | |
| CU20160170A7 (es) | Derivados de carboxamida |